Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.3K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.3K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

16.7K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
16.7K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

83.7K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
83.7K
Metastasis02:30

Metastasis

6.1K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unlocking the ferroptotic window: Lipidomic rewiring and metabolic addiction in EMT-driven breast cancer resistance.

Cell death discovery·2026
Same author

Towards light-coupled sample preparation for time-resolved cryoEM studies.

IUCrJ·2026
Same author

Phenazine Methosulfate Rewires Mitochondrial Redox Circuits to Restore Membrane Potential and ATP Synthesis Under ETC Blockade in Glioblastoma Cells.

Antioxidants (Basel, Switzerland)·2026
Same author

The IKKα-regulated microRNA miR-9-5p mediates lung cancer growth and invasiveness via CDH1/Wnt/β-catenin signalling.

Cell death discovery·2026
Same author

Drop-on-fixed-target reaction initiation approach for serial and time-resolved crystallography.

IUCrJ·2026
Same author

Using cancer profiles to identify synthetic lethal therapeutic targets and predictive biomarkers in cancer gene dependency data.

Bioinformatics (Oxford, England)·2026

Related Experiment Video

Updated: Nov 30, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

474

The structure-function relationship of oncogenic LMTK3.

Angeliki Ditsiou1, Chiara Cilibrasi1, Nikiana Simigdala2

  • 1Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9QG, UK.

Science Advances
|November 14, 2020
PubMed
Summary
This summary is machine-generated.

Researchers identified a small-molecule inhibitor (C28) targeting lemur tyrosine kinase 3 (LMTK3), a protein crucial for cancer cell growth. This inhibitor promotes LMTK3 degradation, offering a promising new avenue for cancer drug development.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.1K

Related Experiment Videos

Last Updated: Nov 30, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

474
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.1K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Lemur tyrosine kinase 3 (LMTK3) signaling is implicated in cancer progression.
  • Understanding LMTK3's role is vital for developing targeted cancer therapies.

Purpose of the Study:

  • To elucidate the structure and function of LMTK3.
  • To identify and characterize a novel small-molecule inhibitor of LMTK3.
  • To evaluate the therapeutic potential of LMTK3 inhibition in preclinical cancer models.

Main Methods:

  • X-ray crystallography to determine LMTK3 kinase domain structure.
  • Phosphoproteomic analysis to identify LMTK3 substrates.
  • High-throughput screening for LMTK3 inhibitors.
  • Biochemical, cellular, and biophysical assays.
  • In vivo studies using xenograft and transgenic mouse models.

Main Results:

  • The crystal structure of LMTK3 kinase domain was solved to 2.1Å resolution.
  • A potent LMTK3 inhibitor, C28, was identified, which promotes proteasome-mediated degradation of LMTK3.
  • LMTK3 was found to be a heat shock protein 90 (HSP90) client protein.
  • Pharmacologic inhibition of LMTK3 reduced cancer cell proliferation and increased apoptosis in breast cancer cells.
  • LMTK3 inhibition demonstrated efficacy in preclinical breast cancer models with no systemic toxicity.

Conclusions:

  • LMTK3 is a druggable target for cancer therapy.
  • The small-molecule inhibitor C28 effectively targets LMTK3, leading to cancer cell death.
  • Targeting LMTK3 represents a promising strategy for developing novel anti-cancer drugs.